PolyModels Hub, a digital biopharma process development platform, secured £7 million in a Series A round led by Molten Ventures with support from Marathon Venture Capital. The investment strengthens efforts to modernize and scale advanced process and regulatory workflows across global pharmaceutical organizations.
PolyModels Hub will use the new capital to grow engineering and product teams, enhance the ModelFlow platform, and expand adoption among biopharma companies. ModelFlow integrates physics-based and AI-driven models with structured workflows, reducing experimental workloads and accelerating process design, testing, and optimization. Early deployments have shown more than a 90% reduction in experimental burden, turning 100-experiment cycles into fewer than ten while maintaining scientific rigor.
PolyModels Hub focuses on transforming traditional, slow, and costly drug development practices. With process development consuming roughly $650 million per drug, scalable digital tools represent a major opportunity for efficiency and reproducibility across small molecules, biologics, and emerging modalities. ModelFlow provides a unified digital environment that helps teams streamline data, improve understanding, and make earlier, confident decisions.
The company is expanding work in complex biologics and AI-driven automation, advancing toward a unified digital layer supporting biopharma from discovery to commercial manufacturing. The team blends life sciences and technology experience, building systems for highly complex, regulated environments.
"The pharmaceutical industry is undergoing a once-in-a-generation digital transformation. In just 18 months, our technology and exceptional team have delivered tangible value across multiple programs, expanding these collaborations to a global scale. We’re investing deeply in complex biologics and advancing our platform to empower scientists with the model-based solutions they deserve to transform molecules into medicines for the 21st century," said Antonio Benedetti, CEO & co-founder, PolyModels Hub.
Ben Wilkinson, CEO, Molten Ventures, added, “PolyModels Hub is solving a real pain point for pharma teams, bringing together deep domain expertise and cutting-edge technology in a way that’s genuinely transformative. We’re proud to support Antonio B, Antonio Y, Harry and the team as they scale their impact across the industry. What impressed us most is the team’s blend of technical know-how and deep understanding of their customers’ challenges. They’ve built a solution that delivers value in weeks, not years, and its rapid adoption across the industry speaks volumes.”
PolyModels Hub continues to connect models, experiments, and decisions in one environment, supporting biopharma teams in moving from complexity to clarity — ultimately accelerating the delivery of better medicines.